TROPION-Lung01 Study Design and Baseline demographics

BEGONIA Arm 7: Dato-DXd + Durvalumab Safety Summary Patients, n (%) Any AEs Grade 3/4 Any treatment-related AEsa Grade 3/4 Any serious AEs Treatment-related AEs leading to discontinuation of any treatments AEs leading to deathb Dose adjustments Dato-DXd dose reduction Dato-DXd dose delay Durvalumab dose delay "Per investigator assessment. "Patient died due to dehydration, unrelated to treatment. AE, adverse event; Dato-DXd, datopotamab deruxtecan; D, durvalumab. Dato-DXd+ D N=62 62 (100) 35 (57) 62 (100) 27 (44) 14 (23) 6 (10) 10 (16) 1 (2) 18 (29) 28 (45) 31 (50) Daiichi-Sankyo Data cutoff. 02 Feb 2023 41

View entire presentation